120 related articles for article (PubMed ID: 26524028)
1. [Analysis of Clinical Curative Efficacy for 91 Cases of Splenic Marginal Lymphoma].
Lyu R; Yi SH; Li ZJ; Liu W; Li H; Xiong WJ; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1309-13. PubMed ID: 26524028
[TBL] [Abstract][Full Text] [Related]
2. [Tumors of lymphoid and hematopoietic tissue of spleen: a clinicopathologic analysis of 53 cases].
Chen DB; Shen DH; Zhang H; Wang Y; Song QJ; Yang SM; Fang XZ
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):775-781. PubMed ID: 29136691
[No Abstract] [Full Text] [Related]
3. [Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry].
Hu Y; Chen Y; Wang LH; Chen X; Fang F; Liu SQ; Wu XQ; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):349-56. PubMed ID: 24763004
[TBL] [Abstract][Full Text] [Related]
4. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
6. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
7. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
[TBL] [Abstract][Full Text] [Related]
8. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
9. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
10. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
Zhang YN; Zheng YY; Zhou XG; Zhang SH; Jin Y; Xie JL; Chen SY; Shi Y; Wu LH
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):243-7. PubMed ID: 19575895
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion].
Lyu R; Yan YT; Yi SH; Wang TY; Deng SH; Liu W; Huang WY; An G; Sui WW; Zou DH; Qiu LG; Li ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):228-233. PubMed ID: 32311893
[No Abstract] [Full Text] [Related]
13. A Single-center Experience in Splenic Diffuse Red Pulp Lymphoma Diagnosis.
Julhakyan HL; Al-Radi LS; Moiseeva TN; Danishyan KI; Kovrigina AM; Glebova SM; Lugovskaya SA; Dvirnik VN; Khvastunova AN; Yakutik IA; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S166-9. PubMed ID: 27131623
[TBL] [Abstract][Full Text] [Related]
14. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of CD5-positive splenic marginal zone lymphoma.
Li Y; Wang G; Liu E; Zhang D; Zhang Y; Jian X; Zhao W; Li W
J Clin Pathol; 2024 May; 77(6):421-425. PubMed ID: 36922019
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
17. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
18. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
Lyu R; Wang T; Wang Y; Xiong W; Wang H; Yan Y; Wang Q; Liu W; An G; Huang W; Sui W; Xu Y; Zou D; Wang J; Qiu L; Yi S
Br J Haematol; 2021 Sep; 194(5):862-869. PubMed ID: 34328213
[TBL] [Abstract][Full Text] [Related]
19. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
20. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
